Impact of food and different meal types on the pharmacokinetics of rilpivirine

Journal of Clinical Pharmacology

Volumn 53, Issue 8, 2013, Pages 834-840

  Crauwels, Herta M ^a   Van Heeswijk, Rolf P G ^a   Buelens, Annemie ^a   Stevens, Marita ^a   Boven, Katia ^a   Hoetelmans, Richard M W ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Food effect; Nonnucleoside reverse transcriptase inhibitor; Pharmacokinetics; Rilpivirine; TMC278

Indexed keywords

RILPIVIRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD COMPOSITION; FOOD INTAKE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INJECTION SITE PAIN; LIPID DIET; MALE; MEAL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PROTEIN DIET; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINGLE DRUG DOSE; TABLET;

FOOD EFFECT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHARMACOKINETICS; RILPIVIRINE; TMC278;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BREAKFAST; CROSS-OVER STUDIES; DIETARY FATS; DIETARY SUCROSE; FASTING; FEMALE; FOOD, FORMULATED; FOOD-DRUG INTERACTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MALE; MEALS; MIDDLE AGED; NITRILES; PROTEINS; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 84885037903     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.107     Document Type: Article

References (23)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Last accessed February 25, 2013.
2. Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the secondgeneration agents. Ann Pharmacother. 2010;44:157-165.
3. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54:718-727.
4. Fulco PP, McNicholl IR. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy. 2009;29:281-294.
5. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278-a novel NNRTI-in treatment-naive HIV-1- infected subjects. AIDS. 2006;20:1721-1726. (Pubitemid 44299363)
6. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24: 55-65.
7. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: Week 192 results from a Phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012;28:437-446.
8. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind activecontrolled trial. Lancet. 2011;378:238-246.
9. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet. 2011;378:229-237.
10. Cohen C, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve, HIV-1- infected patients: Pooled results from the phase 3 double-blind, randomized ECHO and THRIVE trials. JAIDS. 2012;60:33-42.
11. Cohen C, Molina J-M, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomised trials. AIDS. 2013;27:939-950.
12. Mathias AA, Menning M, Wei X, et al. Bioequivalence of the coformulation of emtricitabine/rilpivirine/tenofovir DF. 18th International AIDS Conference, Vienna, Austria, July 18-23 2010. Abstract LBPE17.
13. Hoetelmans R, Van Heeswijk R, Kestens D, et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation. 3rd International AIDS Conference, Rio de Janeiro, Brazil, July 24-27, 2005. Abstract TuPe3.1 B10.
14. Schöller-Gyüre M, Boffito M, Pozniak AL, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy. 2008;28:1215-1222.
15. Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci. 1996;85:525-529. (Pubitemid 26150986)
16. Cai X, Grant DJ, Wiedmann TS. Analysis of the solubilization of steroids by bile salt micelles. J Pharm Sci. 1997;86:372-377. (Pubitemid 27113774)
17. Fleisher D, Li C, Zhou Y, Pao L, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. 1999;36:233-254. (Pubitemid 29178760)
18. SUSTIVA® (Efavirenz) Capsules (50 mg, 200 mg); Tablet (600 mg). Prescribing Information (United States). Bristol-Meyers Squibb Company. Available at: http://packageinserts.bms.com/pi/pi-sustiva.pdf. Last accessed February 26, 2013.
19. Morse GD, Fischl MA, Shelton MJ, et al. Effect of food on the steady-state pharmacokinetics of delavirdine in patients with HIV infection. Clin Drug Investig. 2003;23:255-261. (Pubitemid 36469963)
20. VIRAMUNE® (Nevirapine) Tablet (200 mg); Oral Suspension (50 mg/5 mL). Prescribing Information (United States). Boehringer Ingelheim. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase1/ 4renetnt&folderPath1/4/PrescribingInformation/PIs/Viramune/Viramune.pdf. Last accessed February 26, 2013.
21. Abrahamsson B, Albery T, Eriksson A, et al. Food effects on tablet disintegration. Eur J Pharm Sci. 2004;22:165-172. (Pubitemid 38668681)
22. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS. 2008;3:296-305. (Pubitemid 351521014)
23. Welage LS, Carver PL, Revankar S, et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:1431-1438. (Pubitemid 26066634)